The results suggest that NLRP3 inflammasome participates in the pathophysiology of COVID-19 indicating that NLRP3-activated molecules can used markers of disease severity and are also potential therapeutic target for COVID-19. This evidence concerns the gene NLRP3 and COVID-19.